StandardStandard

Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. / Hughes, D.; Pink, J.; Lane, S. et al.
Yn: British Medical Journal, Cyfrol 343, 31.10.2011, t. 1-14.

Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

HarvardHarvard

APA

CBE

MLA

VancouverVancouver

Hughes D, Pink J, Lane S, Pirmohamed M, Hughes D.A. NV. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. British Medical Journal. 2011 Hyd 31;343:1-14. doi: 10.1136/bmj.d6333

Author

RIS

TY - JOUR

T1 - Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses

AU - Hughes, D.

AU - Pink, J.

AU - Lane, S.

AU - Pirmohamed, M.

AU - Hughes D.A., [No Value]

PY - 2011/10/31

Y1 - 2011/10/31

U2 - 10.1136/bmj.d6333

DO - 10.1136/bmj.d6333

M3 - Article

VL - 343

SP - 1

EP - 14

JO - British Medical Journal

JF - British Medical Journal

SN - 0959-535X

ER -